PATIENTS’ PREFERENCES IN CHOOSING THERAPY FOR RETINAL VEIN OCCLUSIONS
暂无分享,去创建一个
Sharon D. Solomon | E. Bass | N. Bressler | S. Bressler | S. Solomon | A. Schachat | H. Fine | Margaret A. Chang
[1] A. Lindblad,et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14. , 2005, Archives of ophthalmology.
[2] T. Williamson,et al. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. , 2005, American journal of ophthalmology.
[3] H. Flynn,et al. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: it's time for clinical trials. , 2005, Archives of ophthalmology.
[4] S. Sacu,et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. , 2005, Acta ophthalmologica Scandinavica.
[5] C. Evereklioglu,et al. The Efficacy of Intravitreal Triamcinolone Acetonide on Macular Edema in Branch Retinal Vein Occlusion , 2005, European journal of ophthalmology.
[6] Harris A. Jaffee,et al. Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. , 2004, Archives of ophthalmology.
[7] E. Bass,et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. , 2004, Ophthalmology.
[8] R. Haddad,et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. , 2004, Archives of ophthalmology.
[9] C. Puliafito,et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. , 2004, Archives of ophthalmology.
[10] E. Bass,et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. , 2004, American journal of ophthalmology.
[11] M. Maguire. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). , 2004, Ophthalmology.
[12] N. Bressler,et al. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. , 2004, Archives of ophthalmology.
[13] N. Bressler,et al. Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials? , 2004, American journal of ophthalmology.
[14] H. Ozdemir,et al. Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. , 2004, Retina.
[15] J. Holladay,et al. Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.
[16] P. Radice,et al. Optical coherence tomography evaluation of macular edema after radial optic neurotomy in patients affected by central retinal vein occlusion , 2004, Seminars in ophthalmology.
[17] V. Martinez-Castillo,et al. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. , 2003, Archives of ophthalmology.
[18] T. Cox,et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. , 2003, Archives of ophthalmology.
[19] Gary C. Brown,et al. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. , 2003, Ophthalmology.
[20] E. Bass,et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. , 2003, Archives of ophthalmology.
[21] S. Bressler,et al. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. , 2003, Archives of ophthalmology.
[22] M. Ip,et al. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. , 2002, Archives of ophthalmology.
[23] J. Jonas,et al. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion , 2002, Graefe’s Archive for Clinical and Experimental Ophthalmology.
[24] G. Brown,et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients , 2002, The British journal of ophthalmology.
[25] Gary C. Brown,et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. , 2002, Archives of ophthalmology.
[26] Tsuguya Fukui,et al. Utilities Measured by Rating Scale, Time Trade-off, and Standard Gamble: Review and Reference for Health Care Professionals , 2002, Journal of epidemiology.
[27] Gary C. Brown,et al. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion , 2002, Ophthalmic epidemiology.
[28] E. Opremcak,et al. RADIAL OPTIC NEUROTOMY FOR CENTRAL RETINAL VEIN OCCLUSION: A Retrospective Pilot Study of 11 Consecutive Cases , 2001, Retina.
[29] R. Hays,et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. , 2001, Archives of ophthalmology.
[30] Peter P. Wakker,et al. The Utility of Health States After Stroke: A Systematic Review of the Literature , 2001, Stroke.
[31] A. Cruess,et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. , 2001, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[32] G. Brown,et al. Quality of life associated with unilateral and bilateral good vision. , 2001, Ophthalmology.
[33] Gary C. Brown,et al. Utility values associated with blindness in an adult population , 2001, The British journal of ophthalmology.
[34] R. Hays,et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators , 1998 .
[35] E. Bass,et al. Preference Values for Visual States in Patients Planning to Undergo Cataract Surgery , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[36] David J. Wilson,et al. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.
[37] D. Finkelstein,et al. Argon laser photocoagulation for macular edema in branch vein occlusion. , 1986, Ophthalmology.
[38] P. Morse. Prospective rationale for and results of argon laser treatment of patients with branch retinal-vein occlusion. , 1985, Annals of ophthalmology.
[39] S D Miller,et al. Argon laser photocoagulation for macular edema in branch vein occlusion. , 1985, American journal of ophthalmology.
[40] M. Natarajan,et al. Central retinal vein occlusion. , 1984, Indian journal of ophthalmology.
[41] K. Erkiliç,et al. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion , 2006, Eye.
[42] J. Jonas,et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide , 2005, Eye.
[43] Gary C. Brown,et al. A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes , 2004, International Ophthalmology.
[44] S. Fekrat,et al. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. , 2004, American journal of ophthalmology.
[45] J. Lim,et al. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion , 2022 .
[46] G. Beauchamp,et al. The reproducibility of ophthalmic utility values. , 2001, Transactions of the American Ophthalmological Society.
[47] Jennifer I. Lim,et al. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.
[48] G. Brown,et al. Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.
[49] A. Hillis,et al. Baseline and early natural history report. The Central Vein Occlusion Study. , 1993, Archives of ophthalmology.
[50] G. Fish,et al. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Macular Photocoagulation Study Group. , 1987, Archives of ophthalmology.